Forcefield Therapeutics to start £35M Series A in October after scooping ex-Novartis exec John Tsai as new CEO
Former Novartis chief medical officer John Tsai is now a biotech CEO, and one of his first priorities at London, UK-based cardiovascular biotech Forcefield Therapeutics will be to raise £35 million ($42 million) in a Series A round.
“We’re planning on kicking off the Series A in the early part of October… and we’re going to give ourselves a window of about four to six months to try to raise £35 million,” Tsai told Endpoints News in an interview.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.